• Increasing global awareness and screening initiatives are significantly improving early detection rates of sexually transmitted diseases, driving the adoption of advanced diagnostic tools.

• Molecular diagnostics and point-of-care testing are reshaping the market landscape by offering faster, more accurate, and patient-friendly testing solutions.

• Rising prevalence of bacterial and viral infections such as chlamydia, gonorrhea, and HIV continues to propel demand for reliable laboratory and rapid test kits worldwide.

• Public-private collaborations aimed at improving healthcare access and funding for STI screening programs are boosting test availability in developing regions.

• Technological advancements in multiplex assays enable simultaneous detection of multiple pathogens, reducing turnaround time and improving clinical efficiency.

• Rising antibiotic resistance among common STDs is encouraging the development of diagnostic solutions that help guide precise and timely treatment decisions.

• North America and Europe remain key markets due to robust healthcare infrastructure, while Asia-Pacific shows rapid adoption driven by government awareness campaigns and expanding diagnostic networks.

• In November 2023, Medix Biochemica acquired ViroStat, expanding its portfolio of antibodies and antigens used in rapid tests for sexually transmitted infections and strengthening its expertise in infectious disease diagnostics.

• In January 2025, NOWDiagnostics collaborated with the National Alliance of State and Territorial AIDS Directors and Building Healthy Online Communities to distribute its over-the-counter rapid syphilis test through the TakeMeHome initiative, improving access to home-based STD testing solutions.

In this report, the Sexually Transmitted Diseases (STD) Diagnostics Market has been segmented by Product, Application, Technology, Location Of Testing and Geography.

Sexually Transmitted Diseases (STD) Diagnostics Market, Segmentation by Product

The Product axis differentiates market opportunity by the tangible and service layers — instruments & services, consumables and software — which together determine recurring revenue streams and customer lock-in potential.
Suppliers pursue integrated offerings where capital equipment sales are complemented by consumables and recurring service contracts, while software platforms add lifecycle analytics and connectivity for public-health surveillance. Drivers include demand for rapid throughput, decentralised testing and data integration for epidemiology.
Strategic priorities focus on bundled pricing, assay validation partnerships, and managed-service models that reduce procurement friction for labs and point-of-care networks while strengthening long-term revenue visibility.

Instruments & Services

Instruments & Services form the capital backbone of laboratory and point-of-care networks, encompassing analyzers, automation, installation, and maintenance agreements that secure long-term OEM relationships.
Vendors emphasise reliability, throughput and service-level agreements as differentiators, often coupling instrument placement with training and accreditation support to accelerate customer qualification. Challenges include capital constraints for smaller labs and the need to demonstrate total-cost-of-ownership advantages.
Strategies include reagent-rental models, remote diagnostics for uptime, and strategic partnerships with lab networks to scale installations and service footprints.

Consumables

Consumables (reagents, cartridges, swabs) drive recurring revenue and are central to assay economics and margin models; suppliers invest in assay sensitivity/specificity and supply-chain resilience to support high-throughput testing demand.
Companies focus on multiplex assays, ease-of-use for POC formats and validated workflows for regulatory acceptance, while securing manufacturing capacity to avoid stockouts during surge testing periods. Drivers include routine screening programmes and outbreak-responsive testing needs.
Commercial approaches include long-term supply agreements, co-development of assays with instrument partners, and diversified manufacturing footprints to ensure continuity.

Software

Software enables data management, connectivity, LIS integration and public-health reporting — critical capabilities as surveillance systems and decentralised testing expand.
Vendors offer middleware, cloud analytics and secure reporting pipelines to convert test results into actionable epidemiologic insights; interoperability and cybersecurity are major selling points. Drivers include mandates for reportable disease notification and the need for rapid case-tracking.
Strategic plays involve platform licensing, partnerships with public-health agencies, and embedding analytics/AI features to help customers triage and manage caseloads efficiently.

Sexually Transmitted Diseases (STD) Diagnostics Market, Segmentation by Application

The Application axis details the specific disease targets and testing approaches where diagnostic technologies deliver value, including molecular and non-molecular methods that map to clinical- and public-health use cases.
Market participants prioritise high-sensitivity assays for screening (CT/NG, HIV, HPV) and rapid, decentralised tests for outbreak control and clinical decision-making. Drivers include screening guidelines, prenatal and antenatal programmes, and surveillance needs that expand routine testing volumes.
Strategic action points include multiplex panel development, assay validation across specimen types, and partnerships with healthcare providers to integrate testing into care pathways.

CT/NG Testing

CT/NG Testing (Chlamydia trachomatis / Neisseria gonorrhoeae) represents a high-volume screening category with strong demand in sexual-health clinics and primary care; sensitivity and throughput are key competitive factors.
Suppliers focus on NAAT-based assays for high clinical accuracy, multiplexing capability and simplified sample collection to increase uptake in screening programmes. Drivers include public-health screening recommendations and the need to reduce asymptomatic transmission.
Commercial strategies include partnerships with public-health agencies, bundled screening programmes, and provision of integrated sample-to-answer solutions for clinics and labs.

Syphilis Testing

Syphilis Testing is segmented into PCR Testing and Non-PCR Testing modalities, reflecting differences in confirmatory vs. screening use-cases and laboratory capability requirements.
Providers offer treponemal and non-treponemal assays across rapid tests and lab-based platforms; PCR-based approaches support specialised confirmation and outbreak investigation while non-PCR rapid tests enable decentralised screening. Drivers include antenatal screening mandates and resurgence monitoring.
Strategic initiatives include combining point-of-care screening with lab confirmation pathways and developing algorithms that streamline diagnosis while meeting public-health reporting needs.

• PCR Testing

  PCR Testing for syphilis provides high analytical sensitivity and is important for confirmatory diagnostics and research settings, requiring lab infrastructure and specialised workflows.
  Vendors market PCR assays for central labs and reference centres, emphasising analytical performance, multiplexing potential and integration with laboratory automation for throughput and traceability.

• Non-PCR Testing

  Non-PCR Testing includes rapid treponemal and non-treponemal tests used for point-of-care screening, particularly in antenatal clinics and outreach settings where immediacy of result and ease-of-use are essential.
  Suppliers focus on robustness, low-cost per test and simplified interpretation to enable broader screening coverage and linkage to care pathways.

Gonorrhea Testing

Gonorrhea Testing often pairs with CT testing in multiplex NAAT panels and increasingly requires antimicrobial-resistance surveillance components to inform therapy choices.
Suppliers develop assays that balance sensitivity with throughput while building surveillance-friendly workflows and optional resistance markers; partnerships with public-health labs support AMR monitoring. Drivers include evolving treatment guidelines and the need for rapid, accurate diagnosis to limit transmission.
Strategic efforts include providing multiplex panels and integrating sequencing or resistance markers into diagnostic pathways for surveillance-led stewardship.

HSV Testing

HSV Testing is presented as PCR and Non-PCR modalities reflecting diagnostic and serologic needs — PCR for lesion-based detection and typing, non-PCR for serology and screening contexts.
Vendors provide lesion-PCR assays for acute diagnosis and serology for retrospective or epidemiologic assessments, emphasising clinical guidance for appropriate test selection and interpretation. Drivers include clinical management needs and maternal–fetal risk mitigation.
Strategic positioning involves educating clinicians on test utility and offering combined testing workflows to support accurate case management.

• PCR Testing

  PCR Testing for HSV provides rapid lesion confirmation and viral typing, supporting treatment decisions in acute presentations and neonatal-risk assessments.
  Suppliers target hospital and reference labs with validated PCR kits and integration options for high-throughput platforms to ensure rapid turnaround times and reliable typing.

• Non-PCR Testing

  Non-PCR Testing includes serologic assays for HSV antibodies used in epidemiologic studies and certain clinical scenarios where historical exposure assessment is needed.
  Companies provide validated serology platforms and guidance on clinical interpretation to reduce misclassification and inform counselling.

HPV Testing is a major screening application with strong linkages to cervical-cancer prevention programs; high-risk HPV molecular assays and reflex testing strategies shape procurement priorities in screening programmes.
Vendors align with national screening guidelines, offering validated NAATs and self-sampling-friendly workflows to expand reach. Drivers include organised screening programmes and vaccination-era shifts in screening algorithms.
Strategic activities include public-health partnerships, self-sampling validations and integration with cytology workflows to sustain screening coverage.

HIV Testing

HIV Testing spans rapid immunoassays and laboratory-confirmatory molecular testing; integration with linkage-to-care systems and confirmatory algorithms is central to public-health impact.
Suppliers concentrate on high-specificity rapid tests for decentralised screening and robust lab-based confirmatory assays to support treatment initiation and monitoring. Drivers include global screening targets and test-and-treat policies.
Strategic directions emphasise integration with care pathways, affordable screening in high-burden settings and connectivity for surveillance and linkages.

Ureaplasma & Mycoplasma Testing

Ureaplasma & Mycoplasma Testing addresses niche clinical indications including reproductive-health and infertility workups; sensitivity and species-level identification can guide targeted therapy.
Vendors supply molecular panels and targeted assays suitable for specialised clinics and reference labs, often packaging these tests within broader STI panels for convenience. Drivers include clinician demand for pathogen-specific diagnostics and fertility-related screening protocols.
Commercial strategies include bundling with broader panels and educating clinicians on clinical utility to drive appropriate test ordering.

Trichomonas

Trichomonas testing has grown in importance due to its prevalence and treatability; both rapid antigen tests and molecular assays are used depending on setting and throughput needs.
Suppliers provide POC-friendly antigen tests for clinic-based screening and molecular assays for lab confirmation and surveillance, emphasising cost-effectiveness and ease of use in community settings. Drivers include screening recommendations for high-risk populations and reproductive-health programmes.
Strategic activity includes targeted outreach to sexual-health clinics and incorporation into multiplex STI testing panels.

VZV Testing

VZV Testing (Varicella Zoster Virus) includes PCR and non-PCR approaches, used in clinical diagnosis of herpes zoster and in immunocompromised patient management where accurate detection affects antiviral therapy decisions.
Suppliers offer lesion-PCR for rapid confirmation and serology for immune-status assessment, targeting hospital labs and specialised clinics with validated assays. Drivers include clinical management in vulnerable populations and outbreak control in institutional settings.
Strategic focus includes integration with patient-management systems and providing rapid, reliable testing to guide therapy in acute cases.

• PCR Testing

  PCR Testing for VZV delivers rapid and specific lesion confirmation critical for immunocompromised patients and hospital infection-control decisions.
  Vendors position PCR assays for clinical labs with recommendations for specimen types and rapid workflows to ensure timely therapeutic intervention.

• Non-PCR Testing

  Non-PCR Testing (serology and antigen tests) supports immune-status determination and some frontline diagnostics, useful in outpatient and resource-limited contexts.
  Suppliers focus on validated serologic kits and rapid antigen formats that are easy to deploy and interpret in clinical settings.

Others

Others captures additional STD targets and emerging panels that address local epidemiology or niche clinical needs, enabling customised assay portfolios for specialised markets.
Suppliers often commercialise bespoke multiplex panels or offer custom assay development to meet specific clinician or public-health requirements, focusing on rapid validation and regulatory pathways for niche use-cases. Drivers include local disease prevalence and diagnostic gaps identified by public-health agencies.
Strategic approaches include modular panel design and close collaboration with regional reference labs to ensure clinical relevance and uptake.

Sexually Transmitted Diseases (STD) Diagnostics Market, Segmentation by Technology

The Technology axis separates immunoassay, molecular diagnostics and other diagnostic modalities, each offering trade-offs between sensitivity, speed and cost that determine suitability across settings from high-throughput labs to point-of-care clinics.
Molecular diagnostics (NAATs) lead for clinical sensitivity and multiplexing capability while immunoassays and rapid antigen tests provide immediacy for decentralised screening; strategic portfolios often include both to address the full care continuum. Drivers include guideline-driven test selection and the need for rapid case-finding during outbreaks.
Suppliers invest in multiplex NAATs, isothermal molecular platforms for POC use, and robust immunoassay formats to meet diverse customer needs and to enable scalable screening programs.

Immunoassay

Immunoassay technologies (rapid tests, ELISA) excel in point-of-care screening, large-scale seroprevalence studies and low-complexity settings where ease-of-use and speed matter most.
Vendors develop high-specificity formats and validated algorithms for reflex testing to reduce false positives, while offering training and quality-control programmes for decentralised use. Drivers include cost-effectiveness and immediate result delivery for clinical decision-making.
Commercial strategies emphasise ruggedised formats, affordable pricing and integration into screening campaigns to maximise reach.

Molecular Diagnostics

Molecular Diagnostics (PCR, isothermal NAATs) deliver superior analytical sensitivity and multiplexing capability, making them the preferred choice for confirmatory testing and high-throughput laboratory workflows.
Companies focus on assay performance, automation compatibility and sample-to-answer workflows that reduce hands-on time, while also pursuing POC-capable molecular platforms to decentralise high-sensitivity testing. Drivers include clinical accuracy demands and the need for multiplex STI panels.
Strategic moves include partnerships with automation vendors, development of CLIA/CAP-ready solutions, and offering validated panels for bundled screening programmes.

Others

Others includes emerging detection modalities (e.g., sequencing-based surveillance, biosensor platforms) and specialised antigen-detection technologies that address specific use-cases such as AMR detection or ultra-rapid triage.
Vendors pilot these technologies with reference labs and public-health partners to demonstrate utility and scalability before commercial roll-out. Challenges include regulatory pathways and validation across diverse specimen types.
Strategic emphasis is on proof-of-concept studies, targeted deployments and building the evidence base to support wider adoption.

Sexually Transmitted Diseases (STD) Diagnostics Market, Segmentation by Location Of Testing

The Location Of Testing axis delineates where testing is performed — centralised laboratories, public-health labs and point-of-care testing — each with unique operational constraints and procurement processes that influence product design and commercial models.
Centralised labs prioritise throughput and automation, public-health labs emphasise surveillance integration and standardisation, while point-of-care settings demand user-friendly, rapid assays with minimal infrastructure needs. Drivers include decentralisation trends and public-health screening programmes.
Suppliers design modular offerings and support packages that map to each testing location, including remote training, quality assurance and connectivity solutions to ensure consistent result reporting and care linkage.

Laboratory Testing (Commercial/Private Labs)

Laboratory Testing (Commercial/Private Labs) represents high-throughput environments where multiplex NAATs, automation and LIS integration are critical to deliver volume, accuracy and efficient turnaround.
Vendors prioritise validated high-throughput assays, automated extraction and sample-to-answer platforms that reduce per-test cost and support large-scale screening contracts with payers and healthcare networks. Drivers include reimbursement frameworks and centralised testing contracts.
Strategic approaches include enterprise-level service agreements, automation partnerships and data-integration services to streamline lab operations and reporting.

Public Health Labs

Public Health Labs focus on surveillance, outbreak response and confirmatory testing, requiring assays with strong specificity and integration with notifiable-disease reporting systems.
Suppliers collaborate with public-health agencies to provide validated assays, training and reporting connectivity to ensure reliable case capture and epidemiologic insight. Drivers include surveillance mandates and public-health funding cycles.
Strategic activities include funded pilot programs, provision of reference testing services and long-term contracts to support population-level monitoring.

Point Of Care Testing

Point Of Care Testing enables immediate clinical decisions in clinics, emergency departments and outreach settings, requiring lateral-flow or compact molecular formats that prioritise ease-of-use and rapid turnaround.
Vendors develop POC-friendly designs, sample-stable reagents and ruggedised devices while ensuring simple interpretation and connectivity for result transmission. Drivers include the need for rapid diagnosis, linkage to care and testing in resource-limited settings.
Commercial strategies include distributor networks, training programs and bundled test-and-treat pathways to close the loop between diagnosis and treatment.

Sexually Transmitted Diseases (STD) Diagnostics Market, Segmentation by Geography

In this report, the Sexually Transmitted Diseases (STD) Diagnostics Market has been segmented by Geography into five regions: North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

North America

North America is a leading market with advanced laboratory infrastructure, high adoption of molecular diagnostics and integrated public-health systems that favour multiplex NAATs and connected reporting solutions.
Market dynamics include strong private-lab networks, investment in POC molecular platforms and demand for high-throughput automation; suppliers prioritise regulatory approvals, reimbursement strategies and service networks. Drivers include established screening recommendations and payer-supported testing programmes.
Strategic focus includes strengthening distribution, offering managed-service contracts and developing analytics-enabled offerings to meet clinical and surveillance needs.

Europe

Europe emphasises harmonised screening policies in some markets, rigorous regulatory frameworks and growing investment in decentralised testing and surveillance integration.
Vendors align with CE-mark processes, GDPR-compliant data solutions and collaborate with national public-health agencies to support screening and outbreak response. Challenges include varying adoption across countries and reimbursement heterogeneity.
Strategic initiatives include pan-European collaborations, evidence-generation studies and deployment of combined lab and POC offerings to meet diverse national needs.

Asia Pacific

Asia Pacific is a high-growth region driven by expanding healthcare access, rising screening programmes and increasing lab capacity across major markets; affordability and scalability are key considerations for suppliers.
Market entrants focus on cost-optimised assays, decentralised POC formats and partnerships with regional distributors to penetrate clinics and public-health programmes. Drivers include large population screening opportunities and investments in healthcare infrastructure.
Strategic approaches include local manufacturing, tiered product portfolios and collaborations with NGOs and government programmes to scale testing access.

Middle East & Africa

Middle East & Africa present targeted opportunities for expanding screening and outbreak response, though adoption varies due to infrastructure and funding constraints; international aid and pilot programmes often catalyse introductions.
Suppliers typically enter via partnerships with public-health organisations, donor-funded initiatives and regional distributors, offering rugged POC tests and connected reporting solutions to bridge surveillance gaps. Challenges include supply-chain and regulatory variability across countries.
Strategic focus is on demonstration pilots, capacity-building and low-cost, high-impact testing solutions tailored to resource-constrained settings.

Latin America

Latin America shows steady demand driven by national screening programmes, growing laboratory networks and focus on maternal and sexual-health interventions that require reliable STD diagnostics.
Vendors pursue distributor agreements, local validation studies and partnerships with public-health agencies to support sustained screening and surveillance efforts. Drivers include government-led health programmes and increasing laboratory modernisation.
Strategic efforts include tailored financing, technical training and integrated offerings that combine assays, instruments and connectivity to support national programmes.

This report provides an in depth analysis of various factors that impact the dynamics of Sexually Transmitted Diseases (STD) Diagnostics Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers:

• Increasing awareness and education
• Technological advancements in diagnostics
• Rising incidence of STDs globally

• Growing demand for rapid testing: The market for sexually transmitted diseases (STD) diagnostics is witnessing a significant surge in demand for rapid testing methods. This trend is primarily driven by the rising prevalence of STDs worldwide, fueled by changing sexual behaviors, inadequate access to healthcare, and limited awareness regarding prevention strategies. Consequently, there is an urgent need for efficient and accurate diagnostic tools that can enable early detection and timely treatment of infections.

  Rapid testing offers numerous benefits compared to conventional laboratory-based diagnostics. These tests provide faster results, are easy to use, and facilitate point-of-care testing—making them especially valuable in resource-limited settings and areas with high STD prevalence.

  Another major advantage is the minimal sample preparation required for most rapid tests. They can often be administered by non-specialized healthcare personnel, expanding accessibility to a wide range of healthcare environments, including clinics, community health centers, and outreach programs. The simplicity and efficiency of rapid testing are key factors propelling its adoption across the healthcare sector.

Restraints:

• Stigma associated with STD testing
• Limited access to healthcare facilities
• High cost of diagnostic procedures

• Regulatory challenges in some regions- The market for sexually transmitted diseases (STD) diagnostics has witnessed significant growth in recent years, driven by increasing awareness, advancements in diagnostic technologies, and a rising global incidence of STDs. However, a major obstacle for companies operating in this market is navigating the complex regulatory landscape, particularly across different regions. Regulatory challenges vary widely from country to country and can greatly impact the introduction and commercialization of new STD diagnostic products.

  In several regions, companies face stringent regulatory requirements, including lengthy approval processes, complex documentation, and high compliance standards. These barriers can slow market entry and increase costs, making it essential for businesses to develop strong regulatory strategies.Cultural and social dynamics also play a significant role in shaping the regulatory environment for STD diagnostics. In certain parts of the world, stigma surrounding STDs can lead to reluctance among populations and governments to openly address these health issues. This hesitation can slow down the implementation of effective diagnostic programs and influence regulatory decisions. Furthermore, disparities in healthcare infrastructure and unequal access to medical resources add another layer of complexity, making it even harder for companies to achieve regulatory compliance and market penetration.

  Successfully overcoming these regulatory hurdles requires a comprehensive understanding of local regulatory frameworks and proactive engagement with regulatory authorities. Tailored strategies that respect cultural sensitivities and address healthcare infrastructure challenges are crucial for success. Companies that can effectively navigate these complexities will unlock significant opportunities in the global STD diagnostics market, contributing to improved prevention, early detection, and management of sexually transmitted diseases worldwide.

Opportunities:

• Expansion of point-of-care testing
• Emerging markets with untapped potential
• Development of novel diagnostic techniques

• Collaborations for awareness campaigns- In the realm of sexually transmitted diseases (STDs), diagnostics play a vital role in ensuring timely detection and treatment. Early diagnosis is crucial for improving individual health outcomes and strengthening public health management efforts. The global STD diagnostics market has experienced significant growth in recent years, fueled by increasing awareness, shifting sexual behaviors, and advancements in diagnostic technologies.

  Strategic collaborations among various stakeholders including healthcare organizations, government agencies, NGOs, and diagnostic companies are instrumental in raising awareness about STDs, promoting preventive measures, and expanding access to testing and treatment services. These partnerships often drive joint campaigns focused on educating the public about the importance of regular STD screenings, destigmatizing sexual health discussions, and encouraging safe sexual practices. By leveraging platforms such as social media, community outreach programs, and educational initiatives in schools and colleges, these efforts aim to reach diverse populations, addressing misconceptions and overcoming barriers to testing and care.

  Collaborations also extend into research and development efforts, aiming to enhance diagnostic technologies. The focus is on creating tests that are more accessible, affordable, and user-friendly, ensuring that individuals across all demographics can benefit from timely diagnosis and treatment. Ultimately, these collaborative initiatives are essential for combating the spread of STDs, reducing their impact on individuals and communities worldwide, and fostering a more proactive approach to sexual health.

Sexually Transmitted Diseases (STD) Diagnostics Market is characterized by strong competition among leading players, with companies prioritizing advanced diagnostic methods and innovative screening tools. Strategic collaboration and frequent partnerships are enhancing product availability and clinical accessibility. With more than 65% share consolidated among top firms, the competitive environment highlights aggressive strategies driving consistent growth in diagnostic adoption.

Market Structure and Concentration
The STD diagnostics market demonstrates a moderately concentrated structure where established players hold significant dominance. Around 70% of revenues are controlled by leading companies, emphasizing limited room for smaller entrants. This concentration is reinforced through mergers, alliances, and shared distribution networks, shaping competitive balance and ensuring expansion of testing platforms across healthcare settings.

Brand and Channel Strategies
Leading companies emphasize differentiated branding and diversified channel strategies to maintain visibility in diagnostic adoption. Hospital networks, clinics, and digital health platforms account for more than 60% of distribution strength. The integration of direct-to-consumer models, supported by effective marketing and service-based collaboration, is intensifying competition while reinforcing reliable brand identity.

Innovation Drivers and Technological Advancements
Technological advancements in molecular diagnostics and point-of-care testing are transforming the competitive scenario. Over 55% of companies are investing in R&D partnerships to accelerate new innovation. Automated workflows, enhanced detection sensitivity, and data-integrated platforms are becoming central to market differentiation, strengthening industry growth and positioning leaders for long-term diagnostic expansion.

Regional Momentum and Expansion
Regional players are leveraging strong distribution strategies to compete with global brands. More than 50% of market expansion is linked to localized manufacturing, diagnostic awareness programs, and public health collaboration. The rising adoption of rapid screening tools across emerging regions emphasizes momentum driven by affordability and accessibility, balancing competitive forces and accelerating growth.

Future Outlook
The competitive outlook for STD diagnostics is projected to remain intense, with over 65% of firms prioritizing R&D-led innovation and multi-level partnerships. Strategic mergers are expected to reshape market concentration, while digital and decentralized models will fuel further expansion. A forward-looking competitive structure highlights the emphasis on rapid technological advancements, ensuring sustained growth and strong industry evolution.

Key players in Sexually Transmitted Diseases (STD) Diagnostics Market include:

• F. Hoffmann-La Roche Ltd
• Abbott Laboratories
• Danaher Corporation (Cepheid)
• Hologic, Inc.
• bioMérieux SA
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.
• Siemens Healthineers AG
• Becton, Dickinson and Company (BD)
• Bio-Rad Laboratories, Inc.
• DiaSorin S.p.A
• OraSure Technologies, Inc.
• Quest Diagnostics
• Chembio Diagnostics, Inc.
• Trinity Biotech plc

In this report, the profile of each market player provides following information:

• Market Share Analysis
• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis